Hargreaves Lansdown results in the spotlight in wake of Woodford scandal

Thursday will see finals results from Hargreaves Lansdown as well as interims from Hastings, Coca-Cola HBC and Arrow Global

Hargreaves Lansdown - Hargreaves Lansdown under the microscope following Woodford scandal
Woodford's stricken Equity Fund has been suspended since 3 June

Hargreaves Lansdown (LON:HL.) has had quite a challenging last few months, especially in terms of dealing with regulators and politicians attacking the group's business model through its close connections with fund manager Neil Woodford and his stricken Equity Income fund.

On Thursday, the FTSE 100 group will hope for some less negative PR as it published its final results.

“Ultimately, we believe that HL will emerge relatively unscathed but undoubtedly this has knocked confidence in the short term,” said analysts at Peel Hunt.

Beyond this, the analysts expect a good set of results, with profits forecast to rise by 7% despite the stock market wobble during the period, with a boost coming from the new Active Savings service adding client numbers, with more banks signing up to the platform.

Starting to recover after dipping on the recent Woodford issues, the shares now trade at 29 times December 2019 earnings, though Peel Hunt expects rising equity markets to prove a tailwind for future consensus forecasts.

Major announcements expected:

Finals:  Hargreaves Lansdown PLC (LON:HL)

Interims: Arrow Global PLC (LON:ARW), Aviva PLC (LON:AV.), Coca-Cola HBC PLC (LON:CCH), Hastings PLC (LON:HSTG), Tritax Big Box PLC (LON:BBOX), Telecom Egypt S (LON:TEEG), Temple Bar Investment Trust PLC (LON:TMPL)

FTSE 100 ex-dividends: BT Group PLC (LON:BT.A), Diageo plc (LON:DGE), Astrazeneca PLC (LON:AZN), GlaxoSmithKline PLC (LON:GSK)

Economic data: US weekly jobless claims, RICS UK housing market survey


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



VolitionRx CEO highlights 'very strong assay and platform development progress'

VolitionRx Limited's (NYSEAMERICAN:VNRX) president and CEO Cameron Reynolds recaps on what he describes as a year of 'very strong progress' in assay and platform development with its Nu.Q Capture program and epigenetic toolkit Nu.Q Vet. Heading into 2020, Reynolds says the company's well...

2 days, 17 hours ago

2 min read